Request Demo
Recent blog posts
Latest Hotspot
8 min read
Cutaneous polyarteritis nodosa Indication Strategy Report 2026: TNF, Trials and Deals
3 August 2026
2026 Cutaneous polyarteritis nodosa indication strategy covering epidemiology, TNF biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Necrobiotic xanthogranuloma Indication Strategy Report 2026: IL-6, Trials and Deals
3 August 2026
2026 Necrobiotic xanthogranuloma indication strategy covering epidemiology, IL-6 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Erythema elevatum diutinum Indication Strategy Report 2026: TNF, Trials and Deals
3 August 2026
2026 Erythema elevatum diutinum indication strategy covering epidemiology, TNF biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Behcet genital ulcers Indication Strategy Report 2026: TNF, Trials and Deals
3 August 2026
2026 Behcet genital ulcers indication strategy covering epidemiology, TNF biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Eosinophilic cellulitis Indication Strategy Report 2026: IL-5, Trials and Deals
3 August 2026
2026 Eosinophilic cellulitis indication strategy covering epidemiology, IL-5 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Generalized morphea Indication Strategy Report 2026: TGF-beta, Trials and Deals
3 August 2026
2026 Generalized morphea indication strategy covering epidemiology, TGF-beta biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Mechanic hands syndrome Indication Strategy Report 2026: JAK, Trials and Deals
3 August 2026
2026 Mechanic hands syndrome indication strategy covering epidemiology, JAK biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Amyopathic dermatomyositis Indication Strategy Report 2026: IFNAR, Trials and Deals
3 August 2026
2026 Amyopathic dermatomyositis indication strategy covering epidemiology, IFNAR biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Dermatomyositis skin disease Indication Strategy Report 2026: IFNAR, Trials and Deals
3 August 2026
2026 Dermatomyositis skin disease indication strategy covering epidemiology, IFNAR biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Neonatal lupus erythematosus Indication Strategy Report 2026: IFNAR, Trials and Deals
3 August 2026
2026 Neonatal lupus erythematosus indication strategy covering epidemiology, IFNAR biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Rowell syndrome Indication Strategy Report 2026: JAK, Trials and Deals
3 August 2026
2026 Rowell syndrome indication strategy covering epidemiology, JAK biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Tumid lupus erythematosus Indication Strategy Report 2026: JAK, Trials and Deals
3 August 2026
2026 Tumid lupus erythematosus indication strategy covering epidemiology, JAK biology, active trials, transactions, unmet need, competition and market…